San Diego-based clinical-stage biopharmaceutical firm Denovo Biopharma has raised 590 million yuan ($83 million) in a Series C round of financing led by CICC Capital’s innovative biomedical equity investment fund, said the US company in a WeChat post on Monday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
